Navigation Links
Study Shows Therapeutic Potential of Fat-derived Stem Cells Declines As Donor’s Age Rises
Date:12/18/2013

Durham, NC (PRWEB) December 18, 2013

A new study released today in STEM CELLS Translational Medicine demonstrates that the therapeutic value of stem cells collected from fat declines when the cells come from older patients.

“This could restrict the effectiveness of autologous cell therapy using fat, or adipose-derived mesenchymal stromal cells (ADSCs), and require that we test cell material before use and develop ways to pretreat ADSCs from aged patients to enhance their therapeutic potential,” said Anastasia Efimenko, M.D., Ph.D. She and Nina Dzhoyashvili, M.D., were first authors of the study led by Yelena Parfyonova, M.D., D.Sc., at Lomonosov Moscow State University, Moscow.

Cardiovascular disease remains the most common cause of death in most countries. Mesenchymal stromal cells (MSCs), stem cells collected from either bone marrow or adipose tissue, are considered one of the most promising therapeutic agents for regenerating damaged tissue because of their proliferation potential and ability to be coaxed into different cell types. Importantly, they also have the ability to stimulate the growth of new blood vessels, a process known as angiogenesis.

Adipose tissue in particular is considered an ideal source for MSCs because it is largely dispensable and the stem cells are easily accessible in large amounts using a minimally invasive procedure. ADSCs have been used in several clinical trials looking at cell therapy for heart conditions, but most of the studies employed cells taken from relatively healthy young donors rather than sick, older ones — the typical patient when it comes to heart disease.

“We knew that aging and disease itself may negatively affect MSC activities,” Dr. Dzhoyashvili said. “So the aim of our study was to investigate how patient age affects the properties of ADSCs, with special emphasis on their ability to stimulate angiogenesis.”

The team analyzed age-associated changes in ADSCs collected from patients of different age groups, including some with coronary artery disease and some without. The results showed that ADSCs from the older patients in both groups expressed various age markers, including shorter telomeres, and, thus, confirmed that ADSCs did age. Telomeres, the regions of repetitive DNA at the end of a chromosome, protect it from deterioration.

“We showed that ADSCs from older patients both with and without coronary artery disease produced significantly less amounts of angiogenesis-stimulating factors compared with the younger patients in the study and their angiogenic capabilities lessened,” Dr. Efimenko concluded. “The results provide new insight into molecular mechanisms underlying the age-related decline of stem cells’ therapeutic potential.”

“These findings are significant because the successful development of cell therapies depends on a thorough understanding of how age may affect the regenerative potential of autologous cells,” said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.

###

The full article, “Adipose-derived stromal cells (ADSC) from aged patients with coronary artery disease keep MSC properties but exhibit characteristics of aging and have an impaired angiogenic potential,” can be accessed at http://stemcellstm.alphamedpress.org/content/early/2013/12/18/sctm.2013-0014.abstract.

About STEM CELLS Translational Medicine: STEM CELLS TRANSLATIONAL MEDICINE (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (http://www.StemCells.com), in its 31th year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (http://www.TheOncologist.com), also a monthly peer-reviewed publication, in its 18th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines

Read the full story at http://www.prweb.com/releases/2013/12/prweb11432406.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scripps Health Launches Pilot Study of Wireless Vital Signs Device
2. It's All In The Climate: New Study from Research Scientists at Florida International University Predict
3. Marijuana consumption in Washington state is higher than previously estimated, study finds
4. World Health Organization study: Atrial fibrillation is a growing global health concern
5. Pain drugs used in prostate gland removal linked to cancer outcome, Mayo Clinic-led study finds
6. Vanderbilt study: Ancient chemical bond may aid cancer therapy
7. A New “18 Tips To Study Better” Article Teaches People How Improve Their Learning Skills Effectively – V-kool
8. Study on the Peptide Matrixyl® Shows it Can Double Collagen Production, Important for Youthful Skin; Matrixyl® Featured in the Sublime Beauty® Collagen Serum Now on Sale
9. Wake Forest Baptist researchers study alcohol addiction using optogenetics
10. Emotional Carnage - Queendom.com Releases Results of New Study on The Impact of PMS On Women’s Emotional Health
11. Simple Steps to Reduce Risk of Dementia Revealed by 35-Year Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... The Dan Carlisle Agency, an Alabama-owned ... is announcing the launch of a charity drive to raise support and awareness ... and children in Birmingham has grown steadily since the 1980’s, and the Pathways ...
(Date:12/8/2016)... Payne, AL (PRWEB) , ... December 08, 2016 ... ... offering insurance and financial consulting services to residential and commercial clients in the ... awareness and support for Nobis Works. , Since 1977, Nobis Works has built ...
(Date:12/7/2016)... VA (PRWEB) , ... December 07, 2016 , ... ... are celebrating the passage of the most comprehensive mental health systems reform legislation ... the support of the President, and the commitment of our elected officials to ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... of Smart Device Remote Control through a new partnership with Splashtop Inc. This ... strengthens its mobile solutions to help businesses maximize their uptime and productivity. , ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any lab to secure ... data. The team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools ... need to operate in a GLP (Good Laboratory Practice) fashion. , With features designed ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016  Haemonetics Corporation (NYSE: HAE ) has ... an innovative software suite designed to help customers drive efficiency ... of NextGen DMS 4 improves core features and introduces innovations ... liter of plasma collected, enhancing quality and regulatory compliance and ... ...
(Date:12/8/2016)... SINGAPORE , BEIJING , and ... a leading commercial provider of genomic services and solutions with ... a Singapore biotechnology company; and the ... today that NovogeneAIT Genomics Singapore (NovogeneAIT) – a new joint ... whole genome sequencing (WGS) centre at Biopolis, Singapore ...
(Date:12/7/2016)... Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical Trial & ... biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version ... Japan , Kenya , Czech ... , China , Slovakia , ... 2 diabetes mellitus. The patent on Lantus expired in 2014. Lantus ...
Breaking Medicine Technology: